ACTIVE : Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial

ACTIVE : Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial

• Abaloparatide (Tymlos®) is an FDA-approved anabolic agent for postmenopausal women with osteoporosis, at high risk for fragility fractures.

• Abaloparatide has more anabolic and less bone resorption effects when compared to teriparatide (Forteo®).

• It is not recommended in patients with Paget’s disease, unexplained ALP elevation, skeletal tumors, open epiphyses, or prior bone irradiation

Infographic

Reference

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016 Aug 16;316(7):722-33. Erratum in: JAMA. 2017 Jan 24;317(4):442.

>